Next Article in Journal
Non-Adenomatous Non-Epithelial Carcinoma (Hemangiopericytoma) of Prostate Treated with Conservative Surgery Followed by Adjuvant Chemoradiation
Previous Article in Journal
rna Interference and micro-rna–Oriented Therapy in Cancer: Rationales, Promises, and Challenges
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Communication

Regression of Follicular Lymphoma With Devil’s Claw: Coincidence or Causation?

Division of Medical Oncology, British Columbia Cancer Agency and University of British Columbia, Vancouver Island Centre, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada
Curr. Oncol. 2009, 16(4), 67-70; https://doi.org/10.3747/co.v16i4.401
Submission received: 7 May 2009 / Revised: 10 June 2009 / Accepted: 2 July 2009 / Published: 1 August 2009

Abstract

Background: Cancer patients frequently use alternative therapies. Two follicular lymphoma patients who had objective tumour regression after taking Devil’s Claw without cytotoxic therapy are reported here. Methods and Results: Patient 1 presented with coexistent immunoglobulin G plasma cell dyscrasia and stage iiia lymphoma (nodes 5 cm in diameter). Computed tomography scan 10 months later showed partial regression. On enquiry, it was learned that the patient was taking Devil’s Claw and Essiac (Essiac Products Services, Pompano Beach, FL, USA). This patient later developed overt myeloma, at which time he stopped the herbal supplements and underwent high-dose chemotherapy and stem cell transplantation, since which no lymphoma progression has occurred. Patient 2 presented with stage iiia lymphoma (nodes 2.5 cm in diameter). He learned of patient 1 through our lymphoma patient support group and started Devil’s Claw. Computed tomography scan 11 months later showed decreased adenopathy and splenomegaly, which has been sustained for 4 years. Discussion and Conclusions: Devil’s Claw tuberous root has anti-inflammatory properties, probably through suppression of cyclooxygenase 2 (cox-2) and inducible nitric oxide synthase expression. There are no prior reports of anticancer activity. Inhibition of cox-2 has a role in colon cancer prevention, has been implicated in lymphomagenesis, and is associated both with lymphoma stage and with response to treatment. However, spontaneous regression in lymphoma has been reported in 16% of patients in one series, of whom none were on herbal medications or cox-2 inhibitors. The key issue in both these patients is whether disease regression was “spontaneous” or causally related to therapy with Devil’s Claw. The timing of the response suggests a positive effect. Further investigation is warranted, preferably with a cox-2 inhibitor of known purity.
Keywords: low-grade lymphoma; alternative therapy; cox-2 inhibition low-grade lymphoma; alternative therapy; cox-2 inhibition

Share and Cite

MDPI and ACS Style

Wilson, K.S. Regression of Follicular Lymphoma With Devil’s Claw: Coincidence or Causation? Curr. Oncol. 2009, 16, 67-70. https://doi.org/10.3747/co.v16i4.401

AMA Style

Wilson KS. Regression of Follicular Lymphoma With Devil’s Claw: Coincidence or Causation? Current Oncology. 2009; 16(4):67-70. https://doi.org/10.3747/co.v16i4.401

Chicago/Turabian Style

Wilson, Kenneth Scott. 2009. "Regression of Follicular Lymphoma With Devil’s Claw: Coincidence or Causation?" Current Oncology 16, no. 4: 67-70. https://doi.org/10.3747/co.v16i4.401

Article Metrics

Back to TopTop